(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of -37.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.81%.
Novavax's revenue in 2025 is $1,064,651,000.On average, 11 Wall Street analysts forecast NVAX's revenue for 2025 to be $176,148,910,580, with the lowest NVAX revenue forecast at $166,723,968,870, and the highest NVAX revenue forecast at $195,161,292,995. On average, 11 Wall Street analysts forecast NVAX's revenue for 2026 to be $58,993,635,145, with the lowest NVAX revenue forecast at $39,761,879,087, and the highest NVAX revenue forecast at $96,283,904,517.
In 2027, NVAX is forecast to generate $42,145,739,343 in revenue, with the lowest revenue forecast at $23,091,107,190 and the highest revenue forecast at $78,428,514,947.